ArticleCancers2026

Low Rates of Discontinuation Unrelated to Disease Progression with Trastuzumab Deruxtecan in Metastatic Breast Cancer: A Real-World Study.

Luca Licata et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.